Results 101 to 110 of about 60,445 (238)
Acta Ophthalmologica, EarlyView.Abstract Purpose To assess the vision‐related quality of life (VRQoL) in glaucoma patients over 5 years after primary Baerveldt glaucoma implant (BGI) or trabeculectomy (TE) using a secondary analysis of a randomized clinical trial. Methods Patients were randomized to undergo TE or receive a BGI.
Ionela Popescu‐Giovanitsas +4 more
wiley +1 more source
Three years of ocular proton therapy in the Netherlands, clinical results
Acta Ophthalmologica, EarlyView.Abstract Purpose Uveal melanoma (UM) is a rare cancer with rising number of diagnosis (143 diagnoses in 1990 to 226 in 2023) in the Netherlands. Most patients are treated locally with Ruthenium‐106 brachytherapy (±102/year). Patients were referred for proton therapy (PT) to Switzerland in the past, but PT is available in the Netherlands from January ...
C. Rasch +14 more
wiley +1 more source
Comparative Efficacy and Safety of Systemic Immunomodulatory Therapies for Non‐Infectious Uveitis: A Systematic Review With Pairwise and Network Meta‐Analyses [PDF]
PharmacotherapyABSTRACT Introduction Non‐infectious uveitis (NIU) is a chronic immune‐mediated ocular inflammatory disease that may cause irreversible visual impairment. The comparative efficacy and safety of systemic immunomodulatory therapies, including conventional agents and biologics, remain incompletely defined.
Chen K, Chan H, Chan C.
europepmc +2 more sources
Clinical outcomes of the PAUL® glaucoma implant for secondary glaucoma
Acta Ophthalmologica, EarlyView.Abstract Purpose Secondary glaucoma encompasses a broad spectrum of disease entities arising from diverse ocular pathologies and is often refractory to conventional treatment. Glaucoma drainage devices (GDDs) have therefore become an important surgical option.
Carolin Deubel +7 more
wiley +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To evaluate the outcomes of intraluminal stent removal from the Paul glaucoma implant (PGI). Methods A retrospective observational study of all cases undergoing PGI stent removal from August 2022 to August 2025 at a single Danish tertiary centre. Primary endpoints were intraocular pressure (IOP) and IOP‐lowering medications.
Anne Studsgaard +2 more
wiley +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To compare the anatomical and functional outcomes of pars plana vitrectomy (PPV) for primary uncomplicated rhegmatogenous retinal detachment (RRD) with superior versus inferior retinal breaks. Methods This retrospective study included 675 eyes of 675 patients, of which 476 had exclusively superior breaks and 199 had at least one ...
Ioanna Dimakopoulou +7 more
wiley +1 more source
Intravitreal faricimab in patients with nAMD: French data from the Fight Retinal Blindness! Registry
Acta Ophthalmologica, EarlyView.Abstract Purpose To assess real‐world outcomes of intravitreal faricimab in French patients with neovascular age‐related macular degeneration (nAMD) previously treated with vascular endothelial growth factor (VEGF) inhibitors using data from the Fight Retinal Blindness! (FRB!) Registry.
Eloi Debourdeau +11 more
wiley +1 more source
American Journal of Ophthalmology Case ReportsPurpose: To describe the clinical and imaging characteristics of the acute progressive phase of a recently proposed clinical entity, Multizonal Outer Retinopathy and Retinal Pigment Epitheliopathy (MORR), a variant of Acute Zonal Occult Outer Retinopathy
Alexandra Klejn +3 more
doaj +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose Multiple factors play a role in epiretinal membrane (ERM) formation and appear to affect the risk of ERM surgery. We explored whether the use of common systemic and topical medications is associated with ERM surgery in Finland. Methods The main outcome variable was incidence of surgically treated vision‐threatening epiretinal membrane (
Sirpa Loukovaara, Jari Haukka
wiley +1 more source